NPJ Breast Cancer最新文献

Meta-analysis of exome-wide gene burden analysis of breast cancer susceptibility genes. 乳腺癌易感基因全外显子组基因负担分析的meta分析。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-10-03 DOI: 10.1038/s41523-025-00826-8

Jennifer A Collister, Karl Smith-Byrne, Joshua Atkins, Gillian Reeves, David J Hunter

引用次数: 0

Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy. pembrolizumab或化疗治疗转移性三阴性乳腺癌的潜在生物标志物与临床结果的关联

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-10-02 DOI: 10.1038/s41523-025-00814-y

Javier Cortes, Oleg Lipatov, Seock-Ah Im, Anthony Goncalves, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Shoichiro Ohtani, Nadia Harbeck, Sherene Loi, Roberto Salgado, Vassiliki Karantza, Jaime Mejia, Razvan Cristescu, Andrey Loboda, Michael Nebozhyn, Petar Jelinic, Lingkang Huang, Eric P Winer

{"title":"Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy.","authors":"Javier Cortes, Oleg Lipatov, Seock-Ah Im, Anthony Goncalves, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Shoichiro Ohtani, Nadia Harbeck, Sherene Loi, Roberto Salgado, Vassiliki Karantza, Jaime Mejia, Razvan Cristescu, Andrey Loboda, Michael Nebozhyn, Petar Jelinic, Lingkang Huang, Eric P Winer","doi":"10.1038/s41523-025-00814-y","DOIUrl":"10.1038/s41523-025-00814-y","url":null,"abstract":"In the randomized, phase 3 KEYNOTE-119 study, overall survival (OS) was not significantly improved with pembrolizumab 200 mg Q3W versus investigator's choice of chemotherapy in participants with previously treated metastatic TNBC. In this exploratory analysis, we evaluated associations of tumor-infiltrating lymphocytes (TILs), T-cell‒inflamed gene expression profile (TcellinfGEP), BRCA1/BRCA2 mutation (BRCAm) status, homologous recombination deficiency (HRD) status, and tumor mutational burden (TMB) with clinical outcomes. TIL level was associated with improved objective response rate (ORR), progression-free survival (PFS), and OS with pembrolizumab but not with chemotherapy or after adjusting for TcellinfGEP. Associations were also identified between TcellinfGEP and improved ORR, PFS, and OS with pembrolizumab. Participants with TMB ≥ 10 mut/Mb showed a trend toward increased benefit with pembrolizumab versus chemotherapy. No association was seen between BRCAm/HRD status and treatment response. These findings suggest a positive association between TILs, TcellinfGEP, and TMB with clinical outcomes in patients with metastatic TNBC receiving pembrolizumab. ClinicalTrials.gov Identifier: NCT02555657 (date of registration: September 18, 2015).","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"109"},"PeriodicalIF":7.6,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer. 转移性三阴性乳腺癌对新辅助化疗免疫治疗反应的预测因素。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-10-02 DOI: 10.1038/s41523-025-00816-w

Nour Abuhadra, Fresia Pareja, Charlie White, Yuan Chen, Hannah Wen, Esra Dikoglu, Jinae Park, Stephanie Downs-Canner, Larry Norton, George Plitas, Atif Khan, Sarat Chandarlapaty, Pedram Razavi, Mark Robson, Monica Morrow, Giacomo Montagna

{"title":"Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer.","authors":"Nour Abuhadra, Fresia Pareja, Charlie White, Yuan Chen, Hannah Wen, Esra Dikoglu, Jinae Park, Stephanie Downs-Canner, Larry Norton, George Plitas, Atif Khan, Sarat Chandarlapaty, Pedram Razavi, Mark Robson, Monica Morrow, Giacomo Montagna","doi":"10.1038/s41523-025-00816-w","DOIUrl":"10.1038/s41523-025-00816-w","url":null,"abstract":"Metaplastic breast cancer (MpBC) treated with standard chemotherapy has low rates of complete pathological response (pCR)(2-23%). In this study, we evaluate the response to neoadjuvant chemo-immunotherapy (NACI) in early-stage MpBC. Thirty-two stage I-III MpBC patients treated with NACI (KEYNOTE-522 regimen) were prospectively enrolled in an institutional rare tumor program. All MpBC were triple negative; most were of chondromyxoid/matrix-producing (12/32, 38%). The majority had stage II (78%) tumors, 12/32 (37.5%) patients completed NACI, 11/32 (34%) progressed during NACI, and in the remaining 9, NACI was discontinued due to side effects. The pCR rate in the entire cohort was 22% (7/32) and it was statistically higher (5/8, 62%) among patients with high ( ≥ 60%) stromal tumor-infiltrating lymphocytes (sTILs) as compared to patients with < 60% sTILs (1/11, 9%). Most patients received adjuvant systemic therapy (capecitabine 16/32, pembrolizumab 20/32). At a median follow-up of 13 months, there were a total of 2 local recurrences, 10 distant recurrences, and 7 deaths. We demonstrated a modest pCR rate in MpBC with the addition of pembrolizumab (22%). Nonetheless, amongst patients with high sTILs, high pCR rates-comparable to those in the KEYNOTE-522 trial-were observed. These findings suggest that sTILs can be used to triage MpBC patients for NACI.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"110"},"PeriodicalIF":7.6,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Longitudinal changes in gut microbiota composition during endocrine therapy in hormone receptor-positive breast cancer patients. 激素受体阳性乳腺癌患者内分泌治疗期间肠道微生物群组成的纵向变化。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-10-01 DOI: 10.1038/s41523-025-00810-2

Chung-Hsin Tsai, Wei-Ling Huang, Ying-Wen Su, Fang Lee, Chi-Chan Lee, Fang-Yi Li, Horng-Woei Yang, Chien-Yi Lu, Po-Sheng Yang

{"title":"Longitudinal changes in gut microbiota composition during endocrine therapy in hormone receptor-positive breast cancer patients.","authors":"Chung-Hsin Tsai, Wei-Ling Huang, Ying-Wen Su, Fang Lee, Chi-Chan Lee, Fang-Yi Li, Horng-Woei Yang, Chien-Yi Lu, Po-Sheng Yang","doi":"10.1038/s41523-025-00810-2","DOIUrl":"10.1038/s41523-025-00810-2","url":null,"abstract":"This prospective study of 90 breast cancer patients examined gut microbiota composition relative to hormone receptor status and endocrine therapy changes. Initial analysis suggested hormone receptor-negative patients had higher Fusobacteriaceae and Fusobacterium abundance, while hormone receptor-positive patients showed Ruminiclostridium enrichment, though differences lacked statistical significance after correction. Hormone receptor-positive patients without lymph node metastasis demonstrated potentially greater microbial diversity, but associations were non-significant after multiple comparison correction. Longitudinal analysis of 52 hormone receptor-positive patients revealed the most robust finding: statistically significant Blautia increases after hormone therapy and aromatase inhibitor treatment. Tamoxifen showed trends toward increased Lachnospiraceae but lost significance after correction due to small sample size. LHRH agonist treatment demonstrated significant Dialister and Megasphaera increases. This study identified limited but robust associations between gut microbiota and endocrine treatments, with Blautia as the most consistently affected genus across multiple therapies, though most findings require validation in larger cohorts.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"107"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145207023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TRIM39-mediated deubiquitination upregulates RNF168 to evade autophagy-ferroptosis in triple-negative breast cancer. trim39介导的去泛素化上调RNF168以逃避三阴性乳腺癌的自噬-铁下垂。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-10-01 DOI: 10.1038/s41523-025-00779-y

Xiaoli Yao, Xiong Shen, Yue Fan, Hong Wang

引用次数: 0

Evaluating mammographic density's contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors. 评估乳房x线摄影密度对改善基于问卷和多基因因素的乳腺癌风险模型的贡献。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-10-01 DOI: 10.1038/s41523-025-00813-z

Charlotta V Mulder, Xin Yang, Yon Ho Jee, Christopher G Scott, Chi Gao, Yu Cao, Amber N Hurson, Mikael Eriksson, Celine M Vachon, Per Hall, Antonis C Antoniou, Peter Kraft, Gretchen L Gierach, Montserrat Garcia-Closas, Parichoy Pal Choudhury

{"title":"Evaluating mammographic density's contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors.","authors":"Charlotta V Mulder, Xin Yang, Yon Ho Jee, Christopher G Scott, Chi Gao, Yu Cao, Amber N Hurson, Mikael Eriksson, Celine M Vachon, Per Hall, Antonis C Antoniou, Peter Kraft, Gretchen L Gierach, Montserrat Garcia-Closas, Parichoy Pal Choudhury","doi":"10.1038/s41523-025-00813-z","DOIUrl":"10.1038/s41523-025-00813-z","url":null,"abstract":"Incorporation of mammographic density into breast cancer risk models may improve risk stratification for tailored screening and prevention. We evaluated the added value of Breast Imaging Reporting and Data System (BI-RADS) breast density to a validated model combining questionnaire-based risk factors and a 313-variant polygenic risk score (PRS), using the Individualized Coherent Absolute Risk Estimator (iCARE) tool for risk model building and validation. Calibration and discrimination were assessed in three prospective cohorts of European-ancestry women (1468 cases, 19,104 controls): US-based Nurses' Health Study (NHS I and II) and Mayo Mammography Health Study (MMHS); and Sweden-based Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA) study. Analyses were stratified by age (<50, ≥50 years). Adding density modestly improved discrimination: among younger women, AUC increased from 65.6% (95% CI: 61.9-69.3%) to 67.0% (95% CI: 63.5-70.6%); among older women, from 65.5% (95% CI: 63.8-67.2%) to 66.1% (95% CI 64.4-67.8%). Among US women aged 50-70 years, 18.4% were identified at ≥3% 5-year risk with density included, capturing 42.4% of future cases; 7.9% were reclassified, identifying 2.8% more future cases. In Sweden, 10.3% were identified at elevated risk, capturing 29.4% of cases, with 5.3% reclassified and 4.4% more cases identified. Integrating density with established risk factors and PRS may enhance breast cancer risk stratification among European-ancestry women, supporting its potential for clinical utility.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"106"},"PeriodicalIF":7.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145207091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polygenic risk score for breast cancer risk prediction in Asian BRCA1 and BRCA2 pathogenic variants carriers. 亚洲BRCA1和BRCA2致病变异携带者乳腺癌风险预测的多基因风险评分

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-09-30 DOI: 10.1038/s41523-025-00820-0

Mei-Chee Tai, Joe Dennis, Sue K Park, Sung-Won Kim, Jong Won Lee, Nur Tiara Hassan, Ava Kwong, Mikael Hartman, Sook-Yee Yoon, Joanne Ngeow, Yin-Ling Woo, Boyoung Park, Zhi-Lei Wong, Goska Leslie, Manjeet K Bolla, Daniel R Barnes, Michael T Parsons, Penny Soucy, Jacques Simard, Nur Aishah Mohd Taib, Cheng-Har Yip, Douglas F Easton, Georgia Chenevix-Trench, Antonis C Antoniou, Soo-Hwang Teo, Weang-Kee Ho

{"title":"Polygenic risk score for breast cancer risk prediction in Asian BRCA1 and BRCA2 pathogenic variants carriers.","authors":"Mei-Chee Tai, Joe Dennis, Sue K Park, Sung-Won Kim, Jong Won Lee, Nur Tiara Hassan, Ava Kwong, Mikael Hartman, Sook-Yee Yoon, Joanne Ngeow, Yin-Ling Woo, Boyoung Park, Zhi-Lei Wong, Goska Leslie, Manjeet K Bolla, Daniel R Barnes, Michael T Parsons, Penny Soucy, Jacques Simard, Nur Aishah Mohd Taib, Cheng-Har Yip, Douglas F Easton, Georgia Chenevix-Trench, Antonis C Antoniou, Soo-Hwang Teo, Weang-Kee Ho","doi":"10.1038/s41523-025-00820-0","DOIUrl":"10.1038/s41523-025-00820-0","url":null,"abstract":"Polygenic risk scores (PRS) have been shown to be predictive of breast cancer (BC) risk in European BRCA1 and BRCA2 pathogenic variant (PV) carriers, but their utility in Asian populations has not been evaluated. In this study, we evaluated the association of two breast cancer PRS developed for the East Asian general population and three versions of a PRS developed for the European general population in 604 BRCA1 (390 affected by breast cancer) and 785 BRCA2 (552 affected by breast cancer) PV female carriers of Asian ancestry. Only the Asian-based PRS, constructed using approximately 1 million single-nucleotide variations (SNVs), showed a significant association with breast cancer risk (Hazard Ratio per standard deviation (95% Confidence Interval) is 1.47 (1.10-1.95) for BRCA1 and 1.43 (1.04-1.95) for BRCA2). Incorporating this PRS into risk prediction models may improve cancer risk assessment among PV carriers of Asian ancestry.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"105"},"PeriodicalIF":7.6,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer. 非激素受体基底蛋白和调控microrna在乳腺癌中的多效性作用。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-09-29 DOI: 10.1038/s41523-025-00827-7

Kelsey Bruce, Michael Kerin, Vinitha Richard

引用次数: 0

Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives. 乳腺癌中的抗体-药物偶联物：耐药机制和未来治疗前景。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-09-29 DOI: 10.1038/s41523-025-00829-5

Irene Valle, Thomas Grinda, Lorenzo Antonuzzo, Barbara Pistilli

引用次数: 0

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer. 肿瘤特异性主要组织相容性- ii表达预测三阴性乳腺癌患者对atezolizumab联合化疗的病理完全反应。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-09-29 DOI: 10.1038/s41523-025-00828-6

Justin M Balko, Luca Licata, Xiao Qian Wang, Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, Antonio Anton, Stefania Russo, Elena Sevillano, Eva Maria Ciruelos, Richard Greil, Vladimir Semiglazov, Marco Colleoni, Catherine M Kelly, Gabriella Mariani, Lucia Del Mastro, Stefania Zambelli, Giulia Viale, Maurizio Callari, Giuseppe Viale, Lajos Pusztai, Luca Gianni, H Raza Ali, Giampaolo Bianchini

{"title":"Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.","authors":"Justin M Balko, Luca Licata, Xiao Qian Wang, Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, Antonio Anton, Stefania Russo, Elena Sevillano, Eva Maria Ciruelos, Richard Greil, Vladimir Semiglazov, Marco Colleoni, Catherine M Kelly, Gabriella Mariani, Lucia Del Mastro, Stefania Zambelli, Giulia Viale, Maurizio Callari, Giuseppe Viale, Lajos Pusztai, Luca Gianni, H Raza Ali, Giampaolo Bianchini","doi":"10.1038/s41523-025-00828-6","DOIUrl":"10.1038/s41523-025-00828-6","url":null,"abstract":"Adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in early-stage triple-negative breast cancer (TNBC), but a fraction of patients derive benefit. Tumor-specific MHC-II (tsMHC-II) expression has been shown to be a predictive biomarker of pathological complete response (pCR) to neoadjuvant chemo-immunotherapy in early-stage TNBC. We performed biomarker analysis of the phase III NeoTRIP trial where patients were randomized to neoadjuvant carboplatin and nab-paclitaxel±atezolizumab. Imaging mass cytometry was used to assess tsMHC-II expression in tumor samples. TsMHC-II positivity was predefined as ≥5% of tumor cells expressing MHC-II, and at an 80th percentile exploratory cutoff. TsMHC-II positivity was associated with a higher pCR rate in the atezolizumab arm (OR:2.58; P = 0.016), but not in the chemotherapy-only arm (OR:1.37; P = 0.34) and these results were stronger using the exploratory cutoff. TsMHC-II expression is associated with improved response to neoadjuvant chemo-immunotherapy in early TNBC and could represent a clinically useful predictive biomarker for treatment personalization.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"103"},"PeriodicalIF":7.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12480687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0